Powered by

NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis; Initiates Clinical Proof of Concept Study for NFX-179 Gel for the Mitigation of Cutaneous Neurofibromatosis Type-1

Jun 09, 2020 - PR Newswire

PR Newswire

 NFlection Therapeutics, Inc., a biopharma therapeutics developer dedicated to targeting disease pathways to uncover new approaches to fighting rare disease, today announced the closing of a $20 million Series A financing round with investment from venBio Partners and F-Prime Capital. The company also announced the initiation of the first clinical trial of its lead product, NFX-179 Gel, a topically applied therapy.

The Phase 2a study, on the heels of the successfu...